RSV disease-Is there a role for prevention?

Respiratory Medicine

Volumn 95, Issue 3, 2001, Pages 170-172

  Lenney, W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BRONCHODILATING AGENT; PALIVIZUMAB; PLACEBO; POLYCLONAL ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIBAVIRIN; STEROID;

ANIMAL MODEL; BRONCHIOLITIS; CHILD; CHIMPANZEE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; EDITORIAL; HUMAN; INFANT; LOWER RESPIRATORY TRACT INFECTION; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RODENT; SEASONAL VARIATION; VACCINATION; VIRUS INFECTION;

EID: 0034933636     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2000.1018     Document Type: Editorial

References (24)

1. Respiratory syncytial viral infections in infants and young children
2. Efficacy of β agonists in bronchiolitis: A reappraisal and meta-analysis
3. Randomised placebo-controlled trial of nebulised steroids in acute RSV bronchiolitis
4. Prednisolone treatment of respiratory syncytial virus infection: A randomised control trial of 147 infants
5. Nebulised racemic adrenaline in the treatment of acute bronchiolitis in infants and toddlers
6. A randomised trial comparing the efficacy of epinephrine with salbutamol in the treatment of acute bronchiolitis
7. Randomsied double-blind placebo controlled trial of nebulised adrenaline in acute bronchiolitis
8. Does ribavarin impact on the hospital course of children with RSV infection?
9. Early ribavarin treatment of RSV infection in high risk infants
10. No objective benefit from steroids inhaled via a spacer in infants recovering from bronchiolitis
11. Long-tem consequences of respiratory syncytial virus (RSV) bronchiolitis
12. RSV in early life and risk of wheeze and allergy by age 13
13. Respiratory status and allergy 9 to 10 years after acute bronchiolitis
14. Asthma and immunoglobulin E antibodies after RSV bronchiolitis: A prospective cohort study with matched controls
15. An up-date on approaches to the development of RSV and parainfluenza type 3 vaccines
16. Reduction of RSV hospitalisation among premature infants and infants with BPD using RSV immune globulin prophylaxis
17. Palivizumab, a humanised RSV monoclonal antibody, reduces hospitalisation form RSV infection in high-risk infants
18. Palivizumab expanded access study in 1998-9-northern hemisphere
19. First year experience using palivizumab for protection from RSV lower respiratory tract infection
20. RSV infection in children with bronchopulmonary dysplasia
21. Re-hospitalisation for respiratory illness in infants of less than 32 weeks gestation
22. Prevention of RSV infections: Indications for the use of palivizumab and update on the use of RSV-IGIV
23. Palivizumab for the prevention of hospitalisation due to RSV